Bandingkan kaedah
Semak kaedah pilihan anda secara bersebelahan; baris yang berbeza akan diserlahkan.
| Skala Kualiti Hidup bagi Artritis Psoriatik (PsAQoL)× | Indeks Aktiviti Penyakit Spondilitis Ankilosis Mandi (BASDAI)× | |
|---|---|---|
| Bidang | Reumatologi | Reumatologi |
| Keluarga | Process / pipeline | Process / pipeline |
| Tahun asal≠ | 1997 | 1994 |
| Pengasas≠ | McKenna & Doherty | Garrett et al. |
| Jenis | Patient-reported outcome (PRO) | Patient-reported outcome (PRO) |
| Sumber perintis≠ | Soderlin MK, Bergman S. Psychometric properties of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument: Rasch analysis. Arthritis Care Research. 2011;63(11):1589-1595. link ↗ | Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291. link ↗ |
| Alias | PsAQoL, PSAQoL | BASDAI, BAS-DAI |
| Berkaitan | 4 | 4 |
| Ringkasan≠ | The PsAQoL is a disease-specific patient-reported outcome measure of quality of life impact in psoriatic arthritis (PsA), a chronic inflammatory condition affecting joints and skin. Developed by McKenna and Doherty in 1997, PsAQoL comprises 20 items assessing the multidimensional impact of PsA on physical function, emotional well-being, work productivity, and social participation. PsAQoL captures the patient's lived experience of the disease, complementing clinical disease activity measures (CRP, joint counts) and providing a holistic view of treatment benefit in PsA research and practice. | The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials. |
| ScholarGateSet data ↗ |
|
|